Supplementary Data from &lt;i&gt;MGMT&lt;/i&gt; Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials